Salicylamide inhibitors of influenza virus fusion.

Abstract

Structural variation of the quinolizidine heterocycle of the influenza fusion inhibitor BMY-27709 was examined by several topological dissections in order to illuminate the critical features of the ring system. This exercise resulted in the identification of a series of synthetically more accessible decahydroquinolines that retained the structural elements of BMY-27709 important for antiviral activity. The 2-methyl-cis-decahydroquinoline 6f was the most potent influenza inhibitor identified that demonstrated an EC50 of 90 ng/mL in a plaque reduction assay.

• Authors: K D Combrink, H B Gulgeze, K L Yu, B C Pearce, A K Trehan, J Wei, M Deshpande, M Krystal, A Torri, G Luo, C Cianci, S Danetz, L Tiley, N A Meanwell
• Journal: Bioorganic & medicinal chemistry letters (Bioorg Med Chem Lett) Vol. 10 Issue 15 Pg. 1649-52 (Aug 07 2000) ISSN: 0960-894X [Print] England
• PMID: 10937716 (Publication Type: Journal Article)

Chemical References

• Antiviral Agents
• BMY 27709
• Quinolizines
• Salicylamides
• salicylamide

Topics

• Animals
• Antiviral Agents (chemistry, pharmacology)
• Cell Line
• Dogs
• Membrane Fusion (drug effects)
• Orthomyxoviridae (drug effects, physiology)
• Quinolizines (chemistry, pharmacology)
• Salicylamides (chemistry, pharmacology)